Reported Earlier, Vanda Pharmaceuticals Announces NEJM Evidence Publication Of Imsidolimab Phase III Data Ahead Of FDA Action Date December 12, 2026

Benzinga Newsdesk www.benzinga.com Neutral 93.8%